Drug
Lenvatinib Pill
Lenvatinib Pill is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
50%
Ph phase_4
1
25%
Ph phase_2
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Other(1)
Detailed Status
Active, not recruiting2
Completed1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 41 (25.0%)
Trials by Status
completed125%
active_not_recruiting250%
unknown125%
Recent Activity
2 active trials
Showing 4 of 4
active_not_recruitingphase_2
Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative
NCT05113186
completedphase_1
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
NCT03524326
active_not_recruitingphase_1
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
NCT05620134
unknownphase_4
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
NCT04127396
Clinical Trials (4)
Showing 4 of 4 trials
NCT05113186Phase 2
Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative
NCT03524326Phase 1
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma
NCT05620134Phase 1
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
NCT04127396Phase 4
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4